↓ Skip to main content

Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function

Overview of attention for article published in Diabetologia, January 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)

Mentioned by

twitter
8 X users

Citations

dimensions_citation
56 Dimensions

Readers on

mendeley
27 Mendeley
Title
Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function
Published in
Diabetologia, January 2018
DOI 10.1007/s00125-017-4523-9
Pubmed ID
Authors

Xiaoyu He, Qiaohong Lai, Cai Chen, Na Li, Fei Sun, Wenting Huang, Shu Zhang, Qilin Yu, Ping Yang, Fei Xiong, Zhishui Chen, Quan Gong, Boxu Ren, Jianping Weng, Décio L. Eizirik, Zhiguang Zhou, Cong-Yi Wang

Abstract

Post-translational attachment of a small ubiquitin-like modifier (SUMO) to the lysine (K) residue(s) of target proteins (SUMOylation) is an evolutionary conserved regulatory mechanism. This modification has previously been demonstrated to be implicated in the control of a remarkably versatile regulatory mechanism of cellular processes. However, the exact regulatory role and biological actions of the E2 SUMO-conjugating enzyme (UBC9)-mediated SUMOylation function in pancreatic beta cells has remained elusive. Inducible beta cell-specific Ubc9 (also known as Ube2i) knockout (KO; Ubc9Δbeta) and transgenic (Ubc9Tg) mice were employed to address the impact of SUMOylation on beta cell viability and functionality. Ubc9 deficiency or overexpression was induced at 8 weeks of age using tamoxifen. To study the mechanism involved, we closely examined the regulation of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) through SUMOylation in beta cells. Upon induction of Ubc9 deficiency, Ubc9Δbeta islets exhibited a 3.5-fold higher accumulation of reactive oxygen species (ROS) than Ubc9f/f control islets. Islets from Ubc9Δbeta mice also had decreased insulin content and loss of beta cell mass after tamoxifen treatment. Specifically, at day 45 after Ubc9 deletion only 40% of beta cell mass remained in Ubc9Δbeta mice, while 90% of beta cell mass was lost by day 75. Diabetes onset was noted in some Ubc9Δbeta mice 8 weeks after induction of Ubc9 deficiency and all mice developed diabetes by 10 weeks following tamoxifen treatment. In contrast, Ubc9Tg beta cells displayed an increased antioxidant ability but impaired insulin secretion. Unlike Ubc9Δbeta mice, which spontaneously developed diabetes, Ubc9Tg mice preserved normal non-fasting blood glucose levels without developing diabetes. It was noted that SUMOylation of NRF2 promoted its nuclear expression along with enhanced transcriptional activity, thereby preventing ROS accumulation in beta cells. SUMOylation function is required to protect against oxidative stress in beta cells; this mechanism is, at least in part, carried out by the regulation of NRF2 activity to enhance ROS detoxification. Homeostatic SUMOylation is also likely to be essential for maintaining beta cell functionality.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 15%
Researcher 4 15%
Student > Master 3 11%
Student > Doctoral Student 2 7%
Other 2 7%
Other 5 19%
Unknown 7 26%
Readers by discipline Count As %
Medicine and Dentistry 5 19%
Biochemistry, Genetics and Molecular Biology 4 15%
Agricultural and Biological Sciences 3 11%
Neuroscience 2 7%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Other 3 11%
Unknown 8 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2021.
All research outputs
#6,867,449
of 23,015,156 outputs
Outputs from Diabetologia
#2,711
of 5,090 outputs
Outputs of similar age
#138,088
of 442,518 outputs
Outputs of similar age from Diabetologia
#57
of 63 outputs
Altmetric has tracked 23,015,156 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 5,090 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.7. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,518 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.